Update on CO-1686 and AZD9291 race to market in T790M NSCLC
Update from JP Morgan Healthcare 2014 on Clovis Oncology and AstraZeneca race to market with new drugs for treatment of T790M positive non-small cell lung cancer.January 15, 2014
Can Agios score a winner with their anti-cancer metabolism molecules?
Agios Pharmaceuticals is focused on developing new therapies that target mutations in cancer metabolism, including IDH 1 and 2 for AML and Glioblastoma. Will they be successful despite the huge complexity involved in the underlying processes?January 13, 2014
Insights on Foundation Medicine and how molecular testing will transform cancer research
Increasingly, we are seeing the evolution of diagnostic tests in cancer research. Foundation Medicine are using their gene sequencing platform to identify actionable mutations and assist oncologists make better treatment decisions for their patients.January 8, 2014
ASH 2013 Stunning ALL data with Novartis CTL019 CAR Therapy
UPenn and CHOP are using genetically modified chimeric antigen receptor (CAR) T cells to treat patients with B cell cancers such as ALL, B cell NHL, CLL and other B cell malignancies. At ASH, the impressive data from adult and pediatric ALL was presented. This post includes insights on this approach and an interview with Dr Stephan Grupp on the pediatric data.January 9, 2014
Will Exelixis Cabozantinib COMET-1 prostate cancer trial be positive?
The share price of Exelixis ($EXEL) is starting a run-up (after months in the doldrums) in advance of anticipated results from the COMET-1 phase 3 trial in metastatic castrate resistant prostate cancer (mCRPC) for cabozantinib (Cometriq, formerly XL184). Cabozantinib has been shown to significantly improve bone scans and decrease pain, but will it show an improvement in OS?January 6, 2014